Search

Abbott Laboratories

Slēgts

SektorsVeselības aprūpe

105.75 -0.96

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

104.4

Max

107.31

Galvenie mērījumi

By Trading Economics

Ienākumi

-699M

1.1B

Pārdošana

1.4B

13B

P/E

Sektora vidējais

33.383

64.641

EPS

1.31

Dividenžu ienesīgums

2.41

Peļņas marža

9.647

Darbinieki

122,000

EBITDA

-465M

1.8B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+12.16% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

2.41%

2.31%

Nākamie ieņēmumi

2026. g. 14. okt.

Nākamais dividenžu datums

2026. g. 17. aug.

Nākamais Ex dividenžu datums

2026. g. 14. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

16B

180B

Iepriekšējā atvēršanas cena

106.71

Iepriekšējā slēgšanas cena

105.75

Ziņu noskaņojums

By Acuity

21%

79%

48 / 340 Rangs Healthcare

Abbott Laboratories Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. aug. 23:06 UTC

Abbott Laboratories shares are near unchanged in after-market trading, positioned 7.52% above the 20-day moving average and near the upper end of the one-month range.

2026. g. 31. jūl. 23:01 UTC

Abbott Laboratories shares are modestly higher in after-market trading. The stock remains elevated, 7.16% above its 20-day moving average.

2026. g. 30. jūl. 23:51 UTC

Abbott Laboratories shares are higher in after-market trading, recovering from earlier losses. The stock trades significantly above its 20-day moving average.

2026. g. 29. jūl. 23:01 UTC

Abbott Laboratories shares are lower in after-market hours, continuing recent volatility amid mixed global market performance and rising geopolitical tensions in the Middle East.

2026. g. 28. jūl. 23:02 UTC

Abbott Laboratories shares are higher in after-market hours, showing notable volatility post-close while remaining above the 20-day moving average. No specific news was identified.

2026. g. 27. jūl. 23:02 UTC

Abbott Laboratories shares are lower in after-market hours, with no specific news identified to explain the movement. Broader market sentiment may be influencing the decline.

2026. g. 24. jūl. 20:02 UTC

News

A court dismissed a shareholder lawsuit regarding Abbott Laboratories' 2022 infant formula recall, boosting market sentiment as shares trade higher with increased volume.

2026. g. 23. jūl. 23:41 UTC

Abbott Laboratories shares are lower in after-market hours amid broader market weakness, particularly in the bond market, with no specific company news identified.

2026. g. 22. jūl. 22:06 UTC

Abbott Laboratories shares are higher in after-market trading, positioned above their 20-day moving average and near the upper end of their one-month trading range.

2026. g. 21. jūl. 19:01 UTC

Abbott Laboratories is lower today, continuing a decline that began Monday. The stock has dropped from an early peak amid no specific news.

2026. g. 20. jūl. 23:06 UTC

Abbott Laboratories shares are lower in after-market hours, with no specific news identified. Broader market volatility stems from rising Treasury yields and geopolitical tensions.

Salīdzinājums

Cenas izmaiņa

Abbott Laboratories Prognoze

Cenas mērķis

By TipRanks

12.16% augšup

Prognoze 12 mēnešiem

Vidējais 120.15 USD  12.16%

Augstākais 135 USD

Zemākais 112 USD

Pamatojoties uz 15 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Abbott Laboratories — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

15 ratings

15

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

48 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
help-icon Live chat